Therapeutic monoclonal antibodies in oncology.
作者信息
Levene Adam P, Singh Guminder, Palmieri Carlo
机构信息
Department of Cardiology, Leeds General Infirmary, Leeds LS1 3EX, UK.
出版信息
J R Soc Med. 2005 Apr;98(4):146-52. doi: 10.1177/014107680509800403.
Abstract
摘要
相似文献
1
Therapeutic monoclonal antibodies in oncology.
J R Soc Med. 2005 Apr;98(4):146-52. doi: 10.1177/014107680509800403.
2
Monoclonal antibodies as therapeutic agents for cancer.
Lancet Oncol. 2004 May;5(5):292-302. doi: 10.1016/S1470-2045(04)01467-6.
3
The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab.
Recent Pat Biotechnol. 2018;12(2):101-112. doi: 10.2174/1872208311666171122152131.
4
[Anti-cancer monoclonal antibody].
Nihon Rinsho. 2005 Apr;63 Suppl 4:608-12.
5
Monoclonal antibody therapy.
Front Biosci. 2006 May 1;11:1620-35. doi: 10.2741/1909.
6
Monoclonal antibodies in cancer therapy: 25 years of progress.
J Clin Oncol. 2008 Apr 10;26(11):1774-7. doi: 10.1200/JCO.2007.15.7438.
7
Monoclonal antibodies in the treatment of cancer, Part 1.
Am J Health Syst Pharm. 2003 Aug 1;60(15):1531-48. doi: 10.1093/ajhp/60.15.1531.
8
Adverse effects of the humanized antibodies used as cancer therapeutics.
Curr Opin Oncol. 2006 Jul;18(4):316-20. doi: 10.1097/01.cco.0000228734.32261.62.
9
[Progression of antibody therapy in the cancer therapy: anti-CCR4 antibody and others].
Nihon Rinsho Meneki Gakkai Kaishi. 2012;35(2):118-28. doi: 10.2177/jsci.35.118.
10
[Problems in the current target therapy of malignancies].
Vopr Onkol. 2005;51(5):607-11.
引用本文的文献
1
Hybrid IgE-IgG1 antibodies (IgEG): a new antibody class that combines IgE and IgG functionality.
MAbs. 2025 Dec;17(1):2502673. doi: 10.1080/19420862.2025.2502673. Epub 2025 May 16.
2
Immunotherapy in indolent Non-Hodgkin's Lymphoma.
Leuk Res Rep. 2022 May 18;17:100325. doi: 10.1016/j.lrr.2022.100325. eCollection 2022.
3
Direct and indirect engagement of dendritic cell function by antibodies developed for cancer therapy.
Clin Exp Immunol. 2022 Jul 22;209(1):64-71. doi: 10.1093/cei/uxac026.
4
Cancer immunotherapies revisited: state of the art of conventional treatments and next-generation nanomedicines.
Cancer Gene Ther. 2021 Sep;28(9):935-946. doi: 10.1038/s41417-021-00333-5. Epub 2021 Apr 9.
5
The pharmacology and therapeutic applications of monoclonal antibodies.
Pharmacol Res Perspect. 2019 Dec;7(6):e00535. doi: 10.1002/prp2.535.
6
Combining Diagnostic Imaging and Pathology for Improving Diagnosis and Prognosis of Cancer.
Contrast Media Mol Imaging. 2019 Jul 1;2019:9429761. doi: 10.1155/2019/9429761. eCollection 2019.
7
Monoclonal antibodies in cancer immunotherapy.
Mol Biol Rep. 2018 Dec;45(6):2935-2940. doi: 10.1007/s11033-018-4427-x. Epub 2018 Oct 11.
8
Furin targeted drug delivery for treatment of rhabdomyosarcoma in a mouse model.
PLoS One. 2010 May 3;5(5):e10445. doi: 10.1371/journal.pone.0010445.
9
The Use of Phage-Displayed Peptide Libraries to Develop Tumor-Targeting Drugs.
Int J Pept Res Ther. 2006 Mar;12(1):79-91. doi: 10.1007/s10989-005-9002-3. Epub 2006 Mar 3.
10
The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?
Br J Clin Pharmacol. 2008 Jul;66(1):6-19. doi: 10.1111/j.1365-2125.2008.03187.x. Epub 2008 May 22.
本文引用的文献
1
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
N Engl J Med. 2004 Jul 22;351(4):337-45. doi: 10.1056/NEJMoa033025.
2
Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts.
Clin Cancer Res. 2004 Jul 1;10(13):4538-49. doi: 10.1158/1078-0432.CCR-04-0037.
3
Epratuzumab in non-Hodgkin's lymphomas.
Curr Treat Options Oncol. 2004 Aug;5(4):283-8. doi: 10.1007/s11864-004-0019-1.
4
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.
J Clin Oncol. 2004 Jun 1;22(11):2184-91. doi: 10.1200/JCO.2004.11.022.
5
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.
J Clin Oncol. 2004 Apr 1;22(7):1201-8. doi: 10.1200/JCO.2004.10.182. Epub 2004 Mar 1.
6
Targeted molecules in small cell lung cancer.
Semin Oncol. 2004 Feb;31(1 Suppl 1):106-11. doi: 10.1053/j.seminoncol.2003.12.021.
7
Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen.
J Urol. 2003 Dec;170(6 Pt 2):S84-8; discussion S88-9. doi: 10.1097/01.ju.0000095151.97404.7c.
8
Renal cell carcinoma: novel treatments for advanced disease.
Curr Opin Urol. 2003 Nov;13(6):451-6. doi: 10.1097/00042307-200311000-00005.
9
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
N Engl J Med. 2003 Jul 31;349(5):427-34. doi: 10.1056/NEJMoa021491.
10
Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer.
Lancet Oncol. 2003 Jul;4(7):397-406. doi: 10.1016/s1470-2045(03)01137-9.
Zotero 插件